Similarly, in this study Raines and colleagues examined the effect of the PERK inhibitor (GSK2656157) and PHGDH inhibitor (NCT-503) on B16-F10 melanoma xenografts and observed a significant reduction in tumor growth and number of immunosuppressive TAMs. This evidence concerns the gene EIF2AK3 and melanoma.